Squarepoint
HOWL icon

Squarepoint’s Werewolf Therapeutics HOWL Stock Holding History

Squarepoint’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,828
Closed -$11.5K – 4723
2025
Q1 		$11.5K Buy
+11,828
New +$15.5K ﹤0.01% 4459
2024
Q2 		– Sell
-24,594
Closed -$159K – 4311
2024
Q1 		$159K Buy
+24,594
New +$143K ﹤0.01% 3686

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Squarepoint's HOWL Position: Q2 2025 in Review

Squarepoint sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 11,828 shares — an estimated $11.5K sold.

Squarepoint first reported a position in HOWL in Q1 2024 and held it in 2 quarters. The position peaked at $159K in Q1 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Squarepoint reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Squarepoint sold 11,828 Werewolf Therapeutics shares in Q2 2025, an estimated $11.5K.
  • Squarepoint first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 2 quarters.
  • Squarepoint's Werewolf Therapeutics position peaked at $159K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.